{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:51:47Z","timestamp":1780469507276,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ejca.2016.01.006","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T15:31:51Z","timestamp":1458055911000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"special_numbering":"C","title":["Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone"],"prefix":"10.1016","volume":"59","clinical-trial-number":[{"clinical-trial-number":"nct00680992","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6400-3257","authenticated-orcid":false,"given":"Frank","family":"Traub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6170-6694","authenticated-orcid":false,"given":"Janith","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan C.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Mohankumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Blackstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Wunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.01.006_bib1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1302\/0301-620X.92B10.23495","article-title":"The efficacy of chemical adjuvants on giant-cell tumour of bone. An in\u00a0vitro study","volume":"92","author":"Gortzak","year":"2010","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.ejca.2016.01.006_bib2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00264-006-0215-7","article-title":"Giant cell tumour of bone: morphological, biological and histogenetical aspects","volume":"30","author":"Werner","year":"2006","journal-title":"Int Orthop"},{"key":"10.1016\/j.ejca.2016.01.006_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1245\/s10434-009-0803-z","article-title":"Primary malignant giant-cell tumor of bone has high survival rate","volume":"17","author":"Domovitov","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib4","series-title":"Giant cell tumour of Bone","first-page":"321","article-title":"WHO classification of tumours of soft tissue and bone","author":"Fletcher","year":"2013"},{"key":"10.1016\/j.ejca.2016.01.006_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1309\/BPET-F2PE-P2BD-J3P3","article-title":"RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone","volume":"117","author":"Roux","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ejca.2016.01.006_bib6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1359\/jbmr.060604","article-title":"RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone","volume":"21","author":"Atkins","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s004320100234","article-title":"The nature of giant cell tumor of bone","volume":"127","author":"Wulling","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2016.01.006_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone","volume":"10","author":"Balke","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2016.01.006_bib10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2106\/JBJS.D.02771","article-title":"Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy","volume":"90","author":"Becker","year":"2008","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ejca.2016.01.006_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/17453670710014815","article-title":"Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years","volume":"79","author":"Kivioja","year":"2008","journal-title":"Acta Orthopaedica"},{"key":"10.1016\/j.ejca.2016.01.006_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2106\/00004623-199906000-00008","article-title":"Treatment of giant-cell tumors of long bones with curettage and bone-grafting","volume":"81","author":"Blackley","year":"1999","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ejca.2016.01.006_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/BLO.0b013e31805d85e4","article-title":"Joint salvage for pathologic fracture of giant cell tumor of the lower extremity","volume":"459","author":"Deheshi","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s11999-012-2546-6","article-title":"Giant cell tumor with pathologic fracture: should we curette or resect?","volume":"471","author":"van der Heijden","year":"2013","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00003086-200204000-00029","article-title":"Giant cell tumor of long bone: a Canadian Sarcoma Group study","author":"Turcotte","year":"2002","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.blo.0000238784.98606.d4","article-title":"Argon beam coagulation as an adjuvant for local control of giant cell tumor","volume":"454","author":"Lewis","year":"2007","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib17","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.2106\/JBJS.M.00516","article-title":"Liquid nitrogen or phenolization for giant cell tumor of bone? A comparative cohort study of various standard treatments at two tertiary referral centers","volume":"96","author":"van der Heijden","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ejca.2016.01.006_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11999-010-1501-7","article-title":"Giant cell tumor of bone: risk factors for recurrence","volume":"469","author":"Klenke","year":"2011","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib19","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/j.otsr.2013.07.006","article-title":"Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups)","volume":"99","author":"Gouin","year":"2013","journal-title":"Orthop Traumatol Surg Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib21","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib24","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib26","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1245\/s10434-015-4634-9","article-title":"Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone","volume":"22","author":"Rutkowski","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib27","series-title":"Program CTE","article-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","author":"Services UDoHaH","year":"2006"},{"key":"10.1016\/j.ejca.2016.01.006_bib28","first-page":"257","article-title":"Giant-cell tumor and chondrosarcomas: grading, treatment and results (studies of 209 and 131 cases)","author":"Campanacci","year":"1976","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib29","series-title":"Limb salvage in musculoskeletal oncology","first-page":"626","article-title":"Modification of the system for functional evaluation in the surgical management of musculoskeletal tumors","author":"Enneking","year":"1987"},{"key":"10.1016\/j.ejca.2016.01.006_bib30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/BF00540024","article-title":"Development of a measure of physical function for patients with bone and soft tissue sarcoma","volume":"5","author":"Davis","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/(SICI)1096-9098(200004)73:4<206::AID-JSO4>3.0.CO;2-5","article-title":"Predictors of functional outcomes following limb salvage surgery for lower-extremity soft tissue sarcoma","volume":"73","author":"Davis","year":"2000","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib32","first-page":"1","article-title":"Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study","author":"Martin-Broto","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1759720X11424220","article-title":"A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis","volume":"3","author":"Miller","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ejca.2016.01.006_bib34","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.2106\/JBJS.M.01332","article-title":"A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab","volume":"96","author":"Mak","year":"2014","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ejca.2016.01.006_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/03008207.2013.848202","article-title":"Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone","volume":"54","author":"Lau","year":"2013","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bone.2007.08.038","article-title":"Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study","volume":"42","author":"Tse","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ejca.2016.01.006_bib37","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.ejca.2014.06.003","article-title":"Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone","volume":"50","author":"Gouin","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.01.006_bib38","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s11999-015-4249-2","article-title":"A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab","volume":"473","author":"Aponte-Tinao","year":"2015","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2016.01.006_bib39","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2016.01.006_bib40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CCO.0b013e32832c951d","article-title":"Giant cell tumour of bone","volume":"21","author":"Thomas","year":"2009","journal-title":"Curr Opin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T05:22:51Z","timestamp":1536902571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":40,"alternative-id":["S0959804916000447"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.01.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}